Treatment‐driven peripheral blood transcriptomic remodelling and baseline predictors of ESSDAI and STAR response to B‐cell therapy in Sjögren's disease

Study limitation reported by the research below: “The study population is limited to participants in a single GSK trial, which may not represent the broader Sjögren's disease population across different clinical settings or ethnicities.”